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Abstract 
Purpose 
Hyperkalaemia due to potassium-increasing drug-drug interactions (DDIs) is a clinically important 
adverse drug event. The purpose of this study was to identify patient- and physician-related risk 
factors for the development of hyperkalaemia. 
Methods 
The risk for adult patients hospitalised in the University Hospital Zurich of developing 
hyperkalaemia was correlated with (i) patient characteristics, (ii) number, type and duration of 
potassium-increasing DDIs, and (iii) the frequency of serum potassium monitoring. 
Results 
8,413 potentially severe potassium-increasing DDIs were identified in 76,467 patients. (i) Patient-
related characteristics associated with development of hyperkalaemia were: pulmonary allograft 
(RR 5.1; p < 0.0001), impaired renal function (relative risk [RR] 2.7; p < 0.0001), diabetes 
mellitus (RR 1.6; p = 0.002), and female gender (RR 1.5; p = 0.007). (ii) Factors concerning 
medication were: number of concurrently administered potassium-increasing drugs (RR 3.3 per 
additional drug; p < 0.0001) and longer DDI duration (RR 4.9 for durations ≥ 6 days; p < 0.0001). 
(iii) Physician-related factors associated with development of hyperkalaemia were: undetermined 
or elevated serum potassium level before starting treatment (RR 2.2; p < 0.001) and infrequent 
monitoring of serum potassium during DDI (intervals > 48 h; RR 1.6; p < 0.01). 
Conclusion 
Strategies for hyperkalaemia risk reduction during potassium-increasing DDIs should consider 
patient- as well as physician-related risk factors. 
Keywords Drug-drug interactions, Hyperkalaemia, Monitoring, Potassium, risk 
factors 
Introduction 
Although drug-drug interactions (DDIs) are often preventable, they constitute an 
important cause of adverse drug events leading to increased morbidity and 
mortality [1-3]. Potassium-increasing DDIs are among the most common DDIs, 
occurring in up to 10% of hospitalised patients [4,5]. They may induce 
hyperkalaemia and life-threatening cardiac arrhythmias [6]. 
It is a challenge for physicians to identify potentially harmful potassium-
increasing DDIs due to polypharmacy and the increasing number of therapeutic 
agents. Computerized physician order entry (CPOE) in combination with clinical 
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decision support systems (CDSS) may help to detect DDIs and to alert the 
prescribing physicians. However, they are often based on DDI knowledge bases 
which do not take patient characteristics into account, resulting in a low 
specificity of alerts, overalerting and alert fatigue [7-10]. In order to avoid alert 
fatigue on-demand DDI checks have been implemented into the electronic health 
record of the University Hospital Zurich [11]. 
Several studies analysed the risk factors for developing hyperkalaemia during 
potassium-increasing DDIs, focussing on patient-related risk factors such as 
demographic parameters and comorbidities and on medication such as number 
and types of the involved drugs [12-18]. One study considered the effect of 
potassium monitoring during potassium-increasing DDIs in outpatients [19]. To 
our knowledge, no study investigated the effect of physician-related risk factors as 
missing serum potassium measurement at start of therapy and periodicity of serum 
potassium monitoring during drug therapy in hospitalised patients. 
The purpose of this study was to identify patient- and physician-related risk 
factors for the development of hyperkalaemia. They may provide a foundation for 
strategies reducing the risk of hyperkalaemia during potassium-increasing DDIs 
without overalerting. 
Methods 
Setting 
The University Hospital Zurich is a publicly owned, tertiary care academic 
medical centre with 850 beds and 35,000 hospital admissions per year. We 
included all inpatients from 01/12/2009 to 31/12/2011 except for patients on 
dialysis and those hospitalized exclusively in intensive care units. 
The local research ethics committee approved the analyses, and patient consent 
was waived. 
Drug-Drug Interactions and Potassium-Increasing Drugs 
DDIs were identified using the knowledge base galdat/hospINDEX (distributed 
by e-mediat AG, Berne, Switzerland – derived from ABDATA Pharma-Daten 
Service, Werbe- und Vertriebsgesellschaft Deutscher Apotheker, Eschborn, 
Germany), which tiers DDIs by severity (severity level 1: recommended activity 
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‘contraindicated’; 2: ‘contraindicated as precaution‘,3: ‘monitoring or adaptation 
required’, 4: ‘monitoring or adaption in case of risk factors’, 5: ‘monitoring as a 
precaution’, 6: ‘no activity required’) [20]. DDIs with severity levels 1 to 3 were 
considered as severe. 
Potassium-increasing drugs (PIDs) were defined as drugs involved in severe 
potassium-increasing DDIs according to the knowledge base galdat/hospINDEX. 
Thus, PIDs included angiotensin-converting enzyme inhibitors (ACE inhibitors), 
angiotensin antagonists (angiotensin-receptor blockers), direct renin inhibitors, 
immunosuppressive agents (calcineurin inhibitors), potassium-sparing diuretics 
(aldosterone-receptor antagonists and epithelial sodium channel blockers), 
potassium supplements, and trimethoprim (ingredient of cotrimoxazole), 
irrespective of whether these drugs were ordered as a monotherapy or participated 
in a DDI. 
Serum Potassium Measurements 
Serum potassium levels were categorized into 4 groups: (i) hypokalaemia: serum 
potassium ≤ 3.2 mEq/l [21]; (ii) reference range: ≥ 3.3 mEq/l to ≤ 4.5 mEq/l [22]; 
(iii) moderately increased: ≥ 4.6 mEq/l to ≤ 5.4 mEq/l; and (iv) hyperkalaemia: ≥ 
5.5 mEq/l [12]. 
The following parameters, explored for their association with hyperkalaemia, 
need to be defined: 
(i) estimated glomerular filtration rate (GFR) was calculated using the Cockcroft-
Gault equation [23] with the first serum creatinine level measured during DDI ± 1 
day. The kidney dysfunction categories ‘normal’, ‘mild’, and ‘moderate to severe’ 
were assigned to GFR ≥ 90 ml/min, 60 ml/min ≤ GFR < 90 ml/min, and GFR < 
60 ml/min, respectively [24]. 
(ii) Blood transfusions were identified by ICD-9 (International Classification of 
Diseases, World Health Organization, Geneva, Switzerland) treatment code 99.0. 
(iii) Comorbidities were identified using ICD-10 discharge diagnosis codes E10, 
E11, E12, E13, and E14 for diabetes mellitus, code I10 for arterial hypertension, 
code I50 for heart failure, codes I50.11 and I50.12 for NYHA class I/II, codes 
I50.13 and I50.14 for NYHA class III/IV, and code Z94.2 for pulmonary allograft. 
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Statistical Analyses 
Data analyses and statistical tests were performed using the R language and 
environment for statistical computing, version 2.15.1 (R Foundation for Statistical 
Computing, Vienna, Austria). P levels of ≤ 0.05 were considered statistically 
significant. The two-tailed chi-square test was used to analyse categorical data of 
2x2 contingency tables. P levels for multiple comparisons were adjusted using 
Holm correction [25]. Binomial confidence intervals were calculated using the 
Clopper-Pearson method [26]. 
Results 
We analysed data of 76,467 inpatients. Mean duration of hospitalisation for all 
patients was 6.9 days, and 13.5 days for patients with potassium-increasing DDIs. 
Patients’ characteristics are listed in Online Resource 1. 
A total of 1,543,578 drugs were prescribed, resulting in 20.1 drugs per patient on 
average. PIDs accounted for 5.0% of all drug prescriptions. Potassium 
supplements were the most frequently ordered PIDs (30% of all PID 
prescriptions), followed by immunosuppressive agents (21%), ACE inhibitors 
(20%), angiotensin antagonists (14%), trimethoprim (9%), potassium-sparing 
diuretics (6%), and direct renin inhibitors (0.3%). 
Drug-Drug Interactions 
The knowledge base identified 197,351 potential DDIs (2.6 per patient), of which 
90,811 were classified severe (1.2 per patient). The 8,413 potassium-increasing 
DDIs constituted the largest part of level-1 DDIs (972 out of 1’402 DDIs) and 
also played an important role in level-3 DDIs (7’441 out of 84’093 DDIs). 
17% of the potassium-increasing DDIs were started lacking a serum potassium 
measurement within the preceding 48 hours. Moreover, 60 potassium-increasing 
DDIs (0.7%) were ordered despite the presence of hyperkalaemia. The histogram 
of the last serum potassium levels measured within 48 hours prior to a potassium-
increasing DDI showed a bimodal distribution (Fig. 1), with one peak in the 
hypokalaemic range and another one in the reference range. Most of the therapies 
that were started in the hypokalaemic range included a potassium supplement, 
suggesting that they were deliberately prescribed to correct the low potassium. 
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The frequency of daily serum potassium level measurements decreased from 72% 
on the day before DDI to 59% on the first day of DDI and remained between 46% 
and 53% during the next two weeks (the frequencies per day are shown in Online 
Resource 2). 
The intervals between serum level measurements during potassium-increasing 
DDIs present a wide range (median interval 24 hours) with 84.8% of the serum 
level measurements embedded in intervals ≤ 48 hours. Thus, 15.2% of the 
monitoring intervals exceeded 48 hours (the frequency distribution of serum 
potassium monitoring intervals is presented in Online Resource 3). Similar 
monitoring frequencies were observed in surgical and non-surgical specialties. 
The median monitoring period was 1.0 days in both groups. In surgical specialties 
the monitoring intervals exceeded 48 and 96 hours in 14.3% and 2.3%, 
respectively. In non-surgical specialties the respective numbers were 15.6% and 
2.5%. 
Hyperkalaemia 
The occurrences of hyperkalaemia were analysed after the exclusion of DDIs 
started in the presence of hyperkalaemia (60 DDIs in 28 patients), leaving 8,353 
potassium-increasing DDIs in 5,609 patients for further analysis: Hyperkalaemia 
was observed during 161 DDIs concerning 78 patients. A further increased serum 
potassium level of > 6.0 mEq/l occurred during 31 DDIs observed in 15 patients. 
The consideration of the initial serum potassium level and of the serum potassium 
monitoring frequency were two physician-related risk factors for hyperkalaemia: 
(i) Starting a potassium-increasing DDI with either an undetermined or an 
elevated (> 4.5 mEq/l) serum potassium level (2,252 DDIs, 71 with 
hyperkalaemia during DDI) was associated with an increased relative risk (RR) of 
2.2 of developing a hyperkalaemia, compared to starting a DDI at normokalaemic 
or hypokalaemic levels (6,101 DDIs, 90 with hyperkalaemia during DDI; chi-
square test: p < 0.001). (ii) Monitoring intervals exceeding 48 hours during the 
interaction period were associated with a higher risk of hyperkalaemia: A new 
hyperkalaemia was detected in 1.00% (36 out of 3’635) of the serum potassium 
levels measured more than 48 hours after the preceding measurement, compared 
to 0.61% (122 out of 20’092) when levels were measured within 48 (chi-square 
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test: p < 0.01).Three factors regarding medication were associated with 
development of hyperkalaemia: 
(i) The more PIDs were concurrently administered, the higher was the risk for 
hyperkalaemia (Table 1): Starting with a RR of 1 for patients without PIDs, the 
RR increased to 3.9 for PID monotherapies (chi-square test: p < 0.001) and 5.7 for 
therapies with two concurrent PIDs (p = 0.040), peaking at 18.1 for three or more 
concurrent PIDs (p < 0.001). The triple PID combination of immunosuppressive 
agents plus trimethoprim plus ACE inhibitor achieved the highest RR of 29. 
Nevertheless, the absolute risk was low, with hyperkalaemia occurrences of 0.7%, 
1.0 and 3.3% for patients treated with one, with two and with more than two PIDs, 
respectively. 
(ii) The duration of potassium-increasing DDIs was significantly associated with 
hyperkalaemia. 
(iii) A high number of concurrently administered potassium-decreasing drugs 
were associated with higher risk of hyperkalaemia. Blood transfusions showed a 
non-significant trend towards an increased risk of hyperkalaemia. 
Five out of seven electronically available patient-related characteristics predicted 
the development of hyperkalaemia in a univariate analysis (Table 2): (i) female 
gender, (ii) renal impairment, (iii) diabetes mellitus, (iv) pulmonary allograft, and 
(v) serum potassium level exceeding the normokalaemic range before onset of 
potassium-increasing DDI. 
The effect of renal impairment on the risk of hyperkalaemia was analysed in 
greater detail as a function of the number of concurrently administered PIDs (Fig. 
2). The risk significantly increased for patients with moderate to severe kidney 
impairment compared to patients with mild kidney impairment. Hyperkalaemia 
observed during potassium-increasing DDIs was associated with a significantly 
increased risk of transfer to the intensive care unit (ICU) or death (Table 3). The 
risk of death within 2 days after detecting hyperkalaemia was 5.3 times higher 
than for non-hyperkalaemic patients also treated with concurrent PIDs. The 
likelihood of being transferred to the ICU was 1.9 times higher for hyperkalaemic 
patients. Furthermore, the length of hospitalisation increased significantly for 
patients with hyperkalaemia during potassium-increasing DDIs. 
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Discussion 
A number of patient- and physician-related factors have been analysed in order to 
identify characteristics associated with development of hyperkalaemia during 
potassium-increasing DDIs. 
The study demonstrates that physician-related factors affect the risk for 
developing hyperkalaemia in hospitalised patients: (i) Less frequent monitoring of 
serum potassium during DDI was associated with an increased risk of 
hyperkalaemia. Rapid development of hyperkalaemia may be missed with longer 
monitoring intervals [27] and subsequent therapy adjustments may be delayed. 
The frequency of serum potassium level measurements decreased after the first 
day of DDI (as shown in Online Resource 2), despite the finding that the risk of 
hyperkalaemia increased with a longer DDI duration (Table 2). (ii) Furthermore, 
lack of serum level monitoring at onset of potassium-increasing DDIs correlated 
with an increased risk for developing hyperkalaemia (Table 2). Previously such an 
association has been reported for outpatients [19]. 
Medication also affected the risk for hyperkalaemia: (i) As expected, the risk for 
hyperkalaemia increased with the number of concurrently administered PIDs. (ii) 
Surprisingly, the risk of hyperkalaemia also rose with a growing number of 
concurrent potassium-decreasing drugs. A possible explanation for this finding 
might be that potassium-decreasing drugs were used to correct higher serum 
potassium levels. (iii) The level of severity of the involved DDIs was not 
predictive for the likelihood of developing hyperkalaemia. This might be due to 
the frequent usage of the contraindicated level-1 potassium-increasing DDI (i.e. 
the combination of potassium-sparing diuretics with potassium supplements) to 
correct a hypokalaemia (Fig. 1) [10] including a high degree of physician 
awareness [28]. The agreement whether these DDIs should indeed be labelled 
contraindicated is low [29,30]. 
Finally, our study confirmed patient-related characteristics known to be associated 
with development of hyperkalaemia: (i) moderately or severely impaired renal 
function (Fig. 2); (ii) diabetes mellitus [6,31]; (iii) the highest risk concerned 
pulmonary allograft, mainly due to PID combinations of immunosuppressive 
agents, trimethoprim, and ACE inhibitor [32,33]; (iv) female gender, confirming 
another analysis of gender as a predictor in drug-induced hyperkalaemia [34]; (v) 
elevated serum potassium (> 4.5 mEq/l) at onset of the DDI. 
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In contrast to other studies, we couldn’t establish an association between 
hyperkalaemia during potassium-increasing DDIs and age or hospitalisation in 
surgical versus non-surgical specialties [12]. 
There are limitations to our analysis: Dosing of PID prescriptions were not 
considered. Only DDIs between two specific drugs were explored. PIDs not listed 
in the DDI knowledge base, e.g. nonsteroidal anti-inflammatory drugs or heparin, 
were not taken into account. 
The association between the presence of hyperkalaemia during potassium-
increasing DDIs and transfer to the ICU or death within two days was considered 
statistically significant. However, the positive correlation does not imply 
causation, since the relationship is influenced by comorbidities and therapies. 
Overall, the risk of developing hyperkalaemia was low, occurring only in one out 
of fifty potassium-increasing DDIs. This is in line with other reports [28]. 
Despite infrequent occurrences, hyperkalaemias must be detected in order to avoid 
severe complications. Clinical decision support systems may help the prescribing 
physicians to adjust the therapy early. However, unspecific alerts will lead to alert 
fatigue [7-9]. The present study improves the understanding of factors associated 
with hyperkalaemia [12] and adds physician-related factors, which may help to 
design more specific alerts. 
Conclusions 
Strategies for prevention of hyperkalaemia during treatment with potassium-
increasing drugs should consider patient- as well as physician-related 
characteristics: 
Impaired renal function, diabetes mellitus, and pulmonary allograft are important 
patient-related characteristics. A higher number of concurrently administered 
PIDs and a longer DDI duration are risk factors concerning medication. 
Physician-related factors include undetermined or elevated serum potassium 
levels before starting treatment and inadequate frequency of potassium monitoring 
during DDIs. Therefore, measuring serum potassium levels systematically before 
prescribing therapies inducing potassium-increasing interactions and periodic 
monitoring are essential for reducing the risk of hyperkalaemia. 
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Artwork 
Figure Captions 
Fig. 1 Last serum potassium level measured within 48h prior to potassium-
increasing DDIs with and without potassium supplements 
Fig. 2 Occurrences of hyperkalaemia as a function of the number of concurrently 
administered PIDs categorized by the estimated GFR
1
 
Graphics program used to create the artwork 
Fig. 1: R language and environment for statistical computing, version 2.15.1 (R 
Foundation for Statistical Computing, Vienna, Austria) 
Fig. 2: MS Word 2010 with an embedded R graphic 
Caption of electronic supplementary material 
Online Resource 1: patients’ characteristics 
Online Resource 2: Monitoring of serum potassium 
Online Resource 3: Serum potassium monitoring intervals during potassium-
increasing DDIs 
 
                                                 
1
 Inclusion and exclusion criteria base on those of Table 1, whereby only patients including GFR 
estimation were considered. Dots represent the mean; lines encompass a 95% confidence interval. 
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 Table 1 Occurrences of hyperkalaemia as a function of concurrent administration of PIDs 
therapy hyperkalaemia 
No. of concurrent PID 
administrations 
PIDs involved total No. of 
patients
a
 
No. of patients per total 
no PID administration total 30,723 56 0.2 % 
PID monotherapyb total 17,010 122 0.7 % 
concurrent administration of 2 PIDs totalc 4,221 44 1.0 % 
including ACE inhibitor or angiotensin antagonist plus potassium supplement 2,311 24 1.0 % 
 ACE inhibitor or angiotensin antagonist plus potassium-sparing diuretic 824 9 1.1 % 
 Trimethoprimd plus PID 418 3 0.7 % 
 potassium-sparing diuretic plus potassium supplementd 380 6 1.6 % 
 Immunosuppressive agent plus PID 353 2 0.6% 
concurrent administration of 3 or 
more PIDs 
total 1’028 34 3.3 % 
includinge ACE inhibitor or angiotensin antagonist plus potassium-sparing diuretic plus 
potassium supplement 
380 10 2.6 % 
 Immunosuppressive agent plus trimethoprimd plus PID 359 19 5.3 % 
Table 1 Occurrences of hyperkalaemia as a function of ...
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  ACE inhibitor or angiotensin antagonist plus potassium supplement plus 
trimethoprimc 
245 2 0.8 % 
a Patients with at least one serum potassium level measurement within 48h prior to onset of therapy, the last value not being hyperkalaemic (no time restriction for patients with 
no PID administration). 
b involved PIDs (in decreasing order of monotherapy leading to hyperkalaemia): potassium supplements, trimethoprim, immunosuppressive agents (calcineurin inhibitors), ACE 
inhibitors, angiotensin antagonists, potassium-sparing diuretics, and direct renin inhibitors. 
c total of patients exposed < sum of patients exposed, as the same patient might have been considered for two different potassium-increasing DDI groups, if they were not 
overlapping. 
d trimethoprim is part of the combination antibiotic cotrimoxazole (sulfomethoxazole and trimethoprim) used as therapy or prophylaxis for certain infections. 
e concurrent DDIs with less than 100 patient exposed were not considered. 
 Table 2 Development of hyperkalaemia during potassium-increasing DDIs as a function of selected parameters 
Group Characteristic Property Total No. of 
potassium-
increasing DDIs 
No. of potassium-
increasing DDIs with 
hyperkalaemia 
Percentage of DDIs 
with hyperkalaemia 
[%] 
Relative risk 
(95% CI) 
Chi-
square 
test 
Overall   8'353 161 1.9   
Demographics Age (rounded quartiles) < 57y 2'147 54 2.5 1.00 0.0984 
 ≥ 57y, < 66y 2'076 32 1.5 0.62 (0.40-0.95)  
  ≥ 66y, < 75y 1'983 39 2.0 0.79 (0.52-1.19)  
  ≥ 75y 2'147 36 1.7 0.67 (0.44-1.02)  
 Gender male 5'041 80 1.6 1.00 0.0067* 
  female 3'312 81 2.5 1.53 (1.13-2.07)  
Therapy Severity level of potassium-
increasing DDIa 
1 968 20 2.1 1.00 0.8341 
 3 7'385 141 1.9 0.92 (0.58–1.47)  
 Duration of potassium-
increasing DDI (rounded 
quartiles) 
< 1d 1'938 14 0.7 1.00 < 0.0001* 
 ≥ 1d, <3d 2'506 29 1.2 1.60 (0.85-3.01)  
 ≥ 3d, <6d  1'856 46 2.5 3.37 (1.86-6.11)  
 ≥ 6d 2'053 72 3.5 4.72 (2.67-8.35)  
Table 2 Development of hyperkalaemia during ...
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  Number of concurrent 
potassium-decreasing drugsb 
0 2'092 38 1.8 1.00 0.0027* 
 1 4'150 64 1.5 0.85 (0.57-1.27)  
  ≥ 2 2'111 59 2.8 1.52 (1.02-2.28)  
 Recent blood transfusionc no 8'000 148 1.9 1.00 0.0243 
  yes 353 13 3.7 1.96 (1.12-3.41)  
Comorbidities Renal function (estimated 
GFR) 
≥ 90 ml/min 2'429 29 1.2 1.00 < 0.0001* 
 ≥ 60 to < 90 ml/min 2'313 38 1.6 1.37 (0.85-2.21)  
  < 60 ml/min 2'727 87 3.2 2.62 (1.73-3.98)  
  Unknownd 884 7 0.8 0.67 (0.29-1.51)  
 Diabetes mellitus no 6’231 103 1.7 1.00 0.0024* 
  yes 2’122 58 2.7 1.64 (1.19-2.25)  
 Primary arterial hypertension no 3'855 71 1.8 1.00 0.6545 
  yes 4'498 90 2.0 1.08 (0.80-1.48)  
 lung transplant no 7'757 116 1.5 1.00 < 0.0001* 
 yes 596 45 7.6 4.76 (3.41-6.66)  
Progression Last serum potassium before hypokalaemic 1'390 21 1.5 1.03 (0.63-1.67) < 0.0001* 
 parameters onset of DDIe 
normokalaemic 4'711 69 1.5 1.00  
> 4.5 mEq/l 815 36 4.4 2.93 (1.97-4.36)  
Unknownd 1'437 35 2.4 1.65 (1.10-2.46)  
Department  surgical specialties 3'408 63 1.8 1.00 0.7232 
  non-surgical 
specialties 
4'945 98 2.0 1.07 (0.78-1.46)  
a coadministration of potassium-sparing diuretics plus potassium supplements is the only severity level 1 (“contraindicated”) potassium-increasing DDI listed in the used 
knowledge base. All other potassium-increasing DDIs included in this study are classified as severity level 3 DDI (“monitoring or adaptation required”) 
b prescriptions of kaliuretic diuretics coexisting at onset of potassium-increasing DDIs 
c administered between the day prior to DDI and the end of DDI 
d not considered in chi-square test 
e maximum of 48h before onset of DDI 
* significant using Holm correction for multiple testing (with α = 0.05, n = 12) 
 Table 3 Correlation of death, transfer to ICU and length of stay with the presence and absence of 
hyperkalaemia during potassium-increasing DDIs 
 patients with hyperkalaemia 
during potassium-increasing DDIs 
patients without hyperkalaemia 
during potassium-increasing DDIs 
death *1 5/103 (4.9%) a   50/5,506 (0.9%) b 
transfer to ICU *1 9/103 (8.7%) a 245/5,506 (4.5%) b 
length of hospitalisation *2 26.8 ± 26.5d c         12.2 ± 13.8d c 
*1 significant increase (chi-square test: p < 0.05) 
*2 significant increase (Mann-Whitney test: p < 0.001) 
a death respectively transfer to ICU within 2 days of occurrence of hyperkalaemia 
b death respectively transfer to ICU during or less than 2 days after potassium-increasing DDI 
c days; mean ± standard deviation 
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 Online Resource 1 Patients’ characteristics 
 all patients patients with potassium-
increasing DDI 
patients without any 
hyperkalaemia during 
potassium-increasing DDI 
patients with hyperkalaemia 
during potassium-increasing 
DDI 
agea 49.6 ± 23.2y 65.8 ± 13.8y 65.8 ± 13.8y 65.5 ± 15.7y 
gender (females) 50.3% 31.3% 31.0% 45.6% 
comorbities associated 
with hyperkalaemia 
    
impaired renal functionb 13.0% 32.5% 32.0% 58.3% 
diabetes mellitus 9.3% 24.7% 24.6% 35.0% 
arterial hypertension 21.8% 54.8% 54.9% 52.4% 
pulmonary allograft 1.1% 4.1% 3.9% 19.4% 
heart failure 4.3% 20.9% 20.7% 31.1% 
NYHA class I/IIc 1.0% 4.2% 4.2% 4.9% 
NYHA class III/IVc 2.2% 11.6% 11.5% 17.5% 
a mean ± standard deviation 
b estimated glomerular filtration rate < 60 ml/min 
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 Online Resource 2 Monitoring of serum potassium 
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 Online Resource 3 Serum potassium monitoring intervals during potassium-increasing DDIs 
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